PODD

Insulet Corporation

$148.06

-1.17%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.

Source: Yahoo Finance
AI summary

Price & performance

1M+15.1%
3M+17.2%
YTD-44.8%
1Y-50.3%
52-week range—
Beta0.80
Full chart and returns against a benchmark

Q-Score

69/ 100

Quality against peers; 50 is the peer median.

Growth61
Risk67
Performance47
Valuation63
Profitability83
Leverage65
Sentiment30
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$2.7B+30.7%
Net income$247.1M-40.9%
Net margin9.1%-11.1 pts
Historical fundamentals

Red flags in filings

1active red flag
Auditor changeDec 19, 2025
Filings, findings and the timeline

Revenue exposure

28%of revenue from outside the US
United States72%
Non-US28%
Largest customer27%
Regions, segments, customers and suppliers

Valuation

PODDIndustryP/E23.9629.61P/S3.223.49EV/EBITDA15.3618.38P/B6.503.39PEG0.320.32
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report, before the open
EPS estimate$1.59
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate